Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.

<h4>Background</h4>Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in lymphoma patients by inhibiting chemotherapy-induced ovarian follicular damage. However, studies of its clinical efficacy have reported conflicting results.<h4>Met...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yaoyao Zhang, Zhun Xiao, Yan Wang, Shan Luo, Xiaohong Li, Shangwei Li
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8fa9ed1e2b514ab9a10d76c043625302
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8fa9ed1e2b514ab9a10d76c043625302
record_format	dspace
spelling	oai:doaj.org-article:8fa9ed1e2b514ab9a10d76c0436253022021-11-18T08:44:19ZGonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.1932-620310.1371/journal.pone.0080444https://doaj.org/article/8fa9ed1e2b514ab9a10d76c0436253022013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24312222/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in lymphoma patients by inhibiting chemotherapy-induced ovarian follicular damage. However, studies of its clinical efficacy have reported conflicting results.<h4>Method</h4>We conducted a meta-analysis to determine the effect of the preservation of ovarian function by administering GnRHa in young patients with lymphoma undergoing chemotherapy. Seven studies were identified that met inclusion criteria and comprised 434 patients assigned to GnRHa combined chemotherapy or chemotherapy alone.<h4>Results</h4>The incidence of women with premature ovarian failure (POF) demonstrated a statistically significant difference in favor of the use of GnRHa (OR=0.32, 95% CI 0.13-0.77). In addition, the final level of FSH in the GnRH group was significantly lower than control group. (MD= -11.73, 95% CI,-22.25- -1.20), and the final level of AMH in the GnRH group was significantly higher than control group (MD=0.80; 95% CI, 0.61-0.98). However, there was no statistically significant difference between treatment and the control groups in the incidence of a spontaneous pregnancy (OR=1.11; 95% CI, 0.55-2.26).<h4>Conclusion</h4>This meta-analysis suggests that GnRHa may be effective in protecting ovarian function during chemotherapy in lymphoma patients. More well-designed prospective studies are needed to carry out for further understanding of this topic.Yaoyao ZhangZhun XiaoYan WangShan LuoXiaohong LiShangwei LiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e80444 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yaoyao Zhang Zhun Xiao Yan Wang Shan Luo Xiaohong Li Shangwei Li Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
description	<h4>Background</h4>Gonadotropin-releasing hormone agonists (GnRHa) might play a role in preserving ovarian function in lymphoma patients by inhibiting chemotherapy-induced ovarian follicular damage. However, studies of its clinical efficacy have reported conflicting results.<h4>Method</h4>We conducted a meta-analysis to determine the effect of the preservation of ovarian function by administering GnRHa in young patients with lymphoma undergoing chemotherapy. Seven studies were identified that met inclusion criteria and comprised 434 patients assigned to GnRHa combined chemotherapy or chemotherapy alone.<h4>Results</h4>The incidence of women with premature ovarian failure (POF) demonstrated a statistically significant difference in favor of the use of GnRHa (OR=0.32, 95% CI 0.13-0.77). In addition, the final level of FSH in the GnRH group was significantly lower than control group. (MD= -11.73, 95% CI,-22.25- -1.20), and the final level of AMH in the GnRH group was significantly higher than control group (MD=0.80; 95% CI, 0.61-0.98). However, there was no statistically significant difference between treatment and the control groups in the incidence of a spontaneous pregnancy (OR=1.11; 95% CI, 0.55-2.26).<h4>Conclusion</h4>This meta-analysis suggests that GnRHa may be effective in protecting ovarian function during chemotherapy in lymphoma patients. More well-designed prospective studies are needed to carry out for further understanding of this topic.
format	article
author	Yaoyao Zhang Zhun Xiao Yan Wang Shan Luo Xiaohong Li Shangwei Li
author_facet	Yaoyao Zhang Zhun Xiao Yan Wang Shan Luo Xiaohong Li Shangwei Li
author_sort	Yaoyao Zhang
title	Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
title_short	Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
title_full	Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
title_fullStr	Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
title_full_unstemmed	Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
title_sort	gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/8fa9ed1e2b514ab9a10d76c043625302
work_keys_str_mv	AT yaoyaozhang gonadotropinreleasinghormoneforpreservationofovarianfunctionduringchemotherapyinlymphomapatientsofreproductiveageasummarybasedon434patients AT zhunxiao gonadotropinreleasinghormoneforpreservationofovarianfunctionduringchemotherapyinlymphomapatientsofreproductiveageasummarybasedon434patients AT yanwang gonadotropinreleasinghormoneforpreservationofovarianfunctionduringchemotherapyinlymphomapatientsofreproductiveageasummarybasedon434patients AT shanluo gonadotropinreleasinghormoneforpreservationofovarianfunctionduringchemotherapyinlymphomapatientsofreproductiveageasummarybasedon434patients AT xiaohongli gonadotropinreleasinghormoneforpreservationofovarianfunctionduringchemotherapyinlymphomapatientsofreproductiveageasummarybasedon434patients AT shangweili gonadotropinreleasinghormoneforpreservationofovarianfunctionduringchemotherapyinlymphomapatientsofreproductiveageasummarybasedon434patients
_version_	1718421395315097600

Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients.

Ejemplares similares